05494nam 2201297z- 450 991056646260332120231214133246.0(CKB)5680000000037755(oapen)https://directory.doabooks.org/handle/20.500.12854/81051(EXLCZ)99568000000003775520202205d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierRegional Intestinal Drug AbsorptionBiopharmaceutics and Drug FormulationBaselMDPI - Multidisciplinary Digital Publishing Institute20221 electronic resource (238 p.)3-0365-3658-2 3-0365-3657-4 The gastrointestinal tract (GIT) can be broadly divided into several regions: the stomach, the small intestine (which is subdivided to duodenum, jejunum, and ileum), and the colon. The conditions and environment in each of these segments, and even within the segment, are dependent on many factors, e.g., the surrounding pH, fluid composition, transporters expression, metabolic enzymes activity, tight junction resistance, different morphology along the GIT, variable intestinal mucosal cell differentiation, changes in drug concentration (in cases of carrier-mediated transport), thickness and types of mucus, and resident microflora. Each of these variables, alone or in combination with others, can fundamentally alter the solubility/dissolution, the intestinal permeability, and the overall absorption of various drugs. This is the underlying mechanistic basis of regional-dependent intestinal drug absorption, which has led to many attempts to deliver drugs to specific regions throughout the GIT, aiming to optimize drug absorption, bioavailability, pharmacokinetics, and/or pharmacodynamics. In the book "Regional Intestinal Drug Absorption: Biopharmaceutics and Drug Formulation" we aim to highlight the current progress and to provide an overview of the latest developments in the field of regional-dependent intestinal drug absorption and delivery, as well as pointing out the unmet needs of the field.Regional Intestinal Drug Absorption MedicinebicsscPharmaceutical industriesbicsscbioequivalenceBiopharmaceutics Classification Systemin vitrodissolution testpravastatinoral absorptionin silico modelingGastroPlusPhoenix WinNonlinpharmacokineticsclinical studiesibuprofenmanometrygastrointestinalmechanistic modelingPBPKPBBMdisintegrationdissolutionenteric-coatedICHquality controlregional intestinal permeabilitypermeation enhancersabsorption-modifying excipientsoral peptide deliveryintestinal perfusionpharmaceutical developmentcontrolled release drug productbiopharmaceutics classification systemdrug solubilitydrug permeabilitylocation-dependent absorptionsegregated flow intestinal model (SFM)traditional model (TM)route-dependent intestinal metabolismfirst-pass effectdrug-drug interactionsDDIin vitro in vivo extrapolationsIVIVEzero-order absorptionfirst-order absorptioncombined zero- and first-order absorptiontransit compartment absorption modelin situ perfusionmicrodevicesshapemucoadhesioncolon absorptionnutrient digestionnutrient absorptiongastrointestinal hormonepostprandial glycaemiaenergy intakeregion of the gutobesitytype 2 diabetesFranz–PAMPABCS drugsbiomimetic membraneFranz cellpassive drug transportBCS class IV drugssegmental-dependent intestinal permeabilityintestinal absorptionoral drug deliverybiopharmaceuticsphysiologically-based pharmacokinetic (PBPK) modelingfurosemideintestinal permeabilityhuman colon carcinoma cell layer (Caco-2)hierarchical support vector regression (HSVR)drug absorptiondrug solubility/dissolutionregional/segmental-dependent permeability and absorptionMedicinePharmaceutical industriesGonzalez-Alvarez Maria Isabeledt1330868Dahan ArikedtGonzalez-Alvarez Maria IsabelothDahan ArikothBOOK9910566462603321Regional Intestinal Drug Absorption3040001UNINA